Coherus presents promising early clinical data from phase 1 dose expansion study of chs-114 in patients with recurrent/metastatic head and neck squamous cell carcinoma at aacr 2025

– chs-114 demonstrates clinical efficacy and proof of mechanism in hnscc in combination with toripalimab – – confirmed partial response in heavily pretreated pd-1 refractory patient supports expansion in hnscc and gastric cancer in combination with toripalimab – – a second-line phase 1 dose optimization study in hnscc and gastric cancer is ongoing; results expected in the first half of 2026– – coherus to host investor and analyst call with study investigator, dr. douglas adkins, washington university, today at 4:30 p.m. eastern time– redwood city, calif.
CHSCL Ratings Summary
CHSCL Quant Ranking